Abstract: A pharmaceutical composition containing a specific related compound within a specified limit and a method for preparing the same are provided.

Abstract: A pharmaceutical composition containing a specific related compound within a specified limit and a method for preparing the same are provided.

Abstract: A composition comprising an A-B type diblock copolymer or a B-A-B or A-B-A type triblock copolymer with enhanced micelle stability, wherein A is a hydrophilic block and B is a hydrophobic block, and a polymeric micelle composition, a drug carrier composition and a pharmaceutical composition comprising the same are provided.

Abstract: Disclosed are microparticles containing physiologically active peptides, a method for preparing the same, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to a macromolecule for delivering protein, polypeptide or peptide drugs and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs comprising the same, and more specifically relates to a polylactic acid derivative compound of Chemical formula 1 of which the numerical average molecular weight is no more than 7000 daltons and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs using the same and to a production method for the same.

Abstract: A pharmaceutical composition containing a specific related compound in an amount within a specified limit and a method for preparing the same are provided.

Abstract: A pharmaceutical composition containing a specific related compound in an amount below the standard and a method for preparing the same are provided.

Abstract: A pharmaceutical composition containing a specific related compound within a specified limit and a method for preparing the same are provided.

Abstract: A pharmaceutical composition containing a specific related compound in an amount within a specified limit and a method for preparing the same are provided.

Abstract: Disclosed are microparticles containing physiologically active peptides, a method for preparing the same, and a pharmaceutical composition comprising the same.

Abstract: Disclosed are microparticles containing physiologically active peptides, a method for preparing the same, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to a macromolecule for delivering protein, polypeptide or peptide drugs and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs comprising the same, and more specifically relates to a polylactic acid derivative compound of Chemical formula 1 of which the numerical average molecular weight is no more than 7000 daltons and to a production method for the same, as well as to a slow release composition for protein, polypeptide or peptide drugs using the same and to a production method for the same.

Abstract: A method for preparing a biodegradable polymeric micellar composition using liquid polyethylene glycol as a phase separation medium. The present invention also provides an efficient method to effectively incorporate a hydrophobic drug into a polymeric micelle in a polyethylene glycol separating medium.

Abstract: Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or trivalent metal ion, which is obtained by adding the di- or trivalent metal ion to the polymeric composition.

Abstract: A biocompatible stable composition containing a hydrophobic drug, such as paclitaxel. The composition, which forms a syringeable polymeric micellar solution in aqueous or body fluids, is a freeze-dried product comprising a hydrophobic drug, i.e. paclitaxel, and an amphiphilic block copolymer wherein a hydrophobic group having affinity or attraction with the hydrophobic drug, such as paclitaxel, is incorporated on its end.

Abstract: A composition for the sustained delivery of a drug comprising an amphiphilic diblock copolymer; a poorly water-soluble drug; a biodegradable polymer; and liquid poly(ethylene glycol) or functional derivatives thereof and a process for preparing the composition are disclosed. When administered into a particular body site, the composition forms an implant containing the drug and drug containing polymeric micelles, which are slowly released from the implant to maintain a constant drug concentration for an extended period of time.

Abstract: A composition for the sustained delivery of a drug comprising an amphiphilic diblock copolymer; a poorly water-soluble drug; a biodegradable polymer; and liquid poly(ethylene glycol) or functional derivatives thereof and a process for preparing the composition are disclosed. When administered into a particular body site, the composition forms an implant containing the drug and drug containing polymeric micelles, which are slowly released from the implant to maintain a constant drug concentration for an extended period of time.

Abstract: A method for preparing a biodegradable polymeric micellar composition using liquid polyethylene glycol as a phase separation medium. The present invention also provides an efficient method to effectively incorporate a hydrophobic drug into a polymeric micelle in a polyethylene glycol separating medium.

Abstract: The invention is directed to a biocompatible stable composition containing a hydrophobic drug, such as paclitaxel. The composition, which forms a syringeable polymeric micellar solution in aqueous or body fluids, is a freeze-dried product comprising a hydrophobic drug, i.e. paclitaxel, and an amphiphilic block copolymer wherein a hydrophobic group having affinity or attraction with the hydrophobic drug, such as paclitaxel, is incorporated on its end. The invention provides a shelf life of longer than three years in a sterilized container, stability of longer than three days in infusion fluid, has minimal side effects and shows improved bioavailability.